Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face

NANot yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
LentigoSolar LentigoPost Inflammatory Hyperpigmentation
Interventions
DEVICE

CRYONOVE (EC14_4osc)

The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).

DEVICE

CRYONOVE (EC+05_1osc)

The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).

DEVICE

CRYONOVE (EC+05_2osc)

The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cryonove Pharma

INDUSTRY

NCT06305897 - Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face | Biotech Hunter | Biotech Hunter